Speaker illustration

Doctor Jonathan Halperin

Mount Sinai Medical Center, New York (United States of America)

Jonathan L. Halperin, M.D., F.A.C.C., F.A.H.A., F.A.C.P., M.S.V.M. Jonathan L. Halperin is the Robert and Harriet Heilbrunn Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Associate Director of the Cardiovascular Institute at Mount Sinai Medical Center. He was the principal cardiologist responsible for the design and execution of the Stroke Prevention in Atrial Fibrillation (SPAF) clinical trials, and directed the trials that evaluated the first oral direct thrombin inhibitor oral factor Xa inhibitor drugs for this indication. He served as Chair of the ACC/AHA Task Force on Practice Guidelines, Co-Chair of the ACC Clinical Competence Committee, as a member of the FDA Cardiovascular and Renal Drugs Advisory Committee, and is Deputy Editor of The Journal of the American College of Cardiology (JACC).

Enhancing the evidence: latest real-world insights into NOACs for atrial fibrillation

Event: ESC Congress 2022

Topic: Stroke Prevention

Session type: Satellite Symposium

Thumbnail

Roundtable discussion: NOACs in patients with atrial fibrillation and comorbidities

Event: ESC Congress 2021 - The Digital Experience

Topic: Atrial Fibrillation (AF)

Session type: Satellite Symposium

Thumbnail

Dabigatran use in diverse cardiology settings

Event: ESC Congress 2018

Topic: Atrial Fibrillation (AF)

Session type: Satellite Symposium

Thumbnail

Anticoagulation care: covering all the bases

Event: ESC Congress 2017

Topic: Atrial fibrillation (AF)

Session type: Satellite Symposium

Thumbnail

Cardiac emergencies: how can a reversal agent for a NOAC impact practice?

Event: ESC Congress 2016

Topic: Atrial fibrillation (AF)

Session type: Satellite Symposium - Experts on the Spot

Thumbnail

NOACs are not all the same: new factors to consider in 2016

Event: ESC Congress 2016

Topic: Atrial fibrillation (AF)

Session type: Satellite Symposium

Thumbnail

Reversal agents for NOACs: what's available and how do they work?

Event: ESC Congress 2016

Topic: Atrial fibrillation (AF)

Session type: Satellite Symposium - Experts on the Spot

Thumbnail

World-wide clinical use of NOACs: how are we using them?

Event: ESC Congress 2015

Topic: Atrial fibrillation (AF)

Session type: Satellite Symposium - Experts on the Spot

Thumbnail

Practical patient protection: celebrating the benefits of dabigatran 5 years on from RE-LY®

Event: ESC CONGRESS 2014

Topic: Atrial fibrillation (AF)

Session type: Satellite Symposium

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb